The National Kidney Foundation Dialysis Outcomes Quality Initiative (NKF-DOQI) has set forth guidelines to minimize the number of patients with central venous catheters (CVCs) while maximizing the number of patients with functional hemodialysis (HD) accesses. 1 Because of their superior patency, fewer complications, lower associated costs and lower mortality, the Fistula First Initiative has recommended that at least 65% of current HD accesses be autogenous arteriovenous fistulas (AVFs). [1] [2] [3] [4] [5] [6] [7] [8] [9] However, AVFs are classically avoided in patients with inadequate superficial venous anatomy because of the risk of nonmaturation, and an arteriovenous graft (AVG) is often performed instead.
In an attempt to further increase the prevalence of autogenous HD access, Bazan and Schanzer 10 described the use of the brachial vein as the outflow for an AVF.
Since that first described experience of a brachial artery-brachial vein arteriovenous fistula (BVAVF), a number of studies have demonstrated varied results for its rates of patency and complications. [11] [12] [13] [14] [15] [16] [17] [18] Few studies have compared the BVAVF directly with the AVG.
In addition, whether one should perform a BVAVF or an AVG as the initial access in access-naïve patients with inadequate superficial venous anatomy is not well defined. We hypothesized that in patients with inadequate superficial venous anatomy, outcomes after a BVAVF would be superior to those with an AVG, especially in access-naïve patients.
METHODS
The Harbor-University of California, Los Angeles Medical Center Institutional Review Board approved this study. The approval included a waiver of patient consent because the study was retrospective, would not affect patient care prospectively, and contained only deidentified data.
Study design. The study included all consecutive patients who underwent a BVAVF or an AVG between July 2009 and July 2014. Our policy is that the BVAVF is the fourth-line AVF option (after radiocephalic, brachiocephalic, and brachiobasilic), and is thus only performed when superficial veins are inadequate. Similarly, AVGs are also reserved for patients with inadequate superficial venous vasculature as determined by preoperative physical examination, duplex ultrasound (US) imaging, or intraoperative vein measurement. Thus, all patients in this study demonstrated poor superficial venous anatomy. In general, we require a minimum cephalic or basilic vein diameter of 2.5 mm to perform an AVF.
In addition, AVGs are also used in patients who are already supported with HD or those who will likely require HD earlier than an AVF would be able to mature. However, the ultimate decision about whether to perform a BVAVF or an AVG in patients with poor superficial venous anatomy is at the discretion of the attending surgeon. Patient histories, operative details, and data from subsequent follow-up in vascular surgery and nephrology clinics were collected. Patients lost to follow-up were excluded.
Technical notes. All BVAVFs were performed in two stages, with formation of the anastomosis at the initial surgery and subsequent transposition after 4 to 6 weeks. BVAVFs were determined to be mature if they had a minimum intraluminal diameter of 6 mm and demonstrated a flow of 600 mL/min on duplex ultrasound imaging. BVAVFs were transposed using two different methods: one using a longitudinal incision along the upper arm, with placement of the transposed vein in a newly created subcutaneous pocket 3 to 4 mm from the skin, and the other more common method using a similar incision but with transection, tunneling, and reanastomosis of the vein at the level of the prior anastomosis. In both instances all venous tributaries are ligated and divided. We require a minimum brachial vein diameter of 2.5 mm verified by direct measurement as well as the ability to accommodate a 2.5-mm dilator after dilation with heparinized saline. Anastomoses are performed in an end vein-to-side artery fashion with a minimum arteriotomy of 6 mm.
Our standard AVG is performed exclusively using a polytetrafluoroethylene (PTFE) graft. The decision whether to use a 4-mm to 7-mm tapered PTFE graft is at the discretion of the attending surgeon. AVGs are performed from the brachial artery to the brachial, basilic, and axillary veins. Forearm AVGs are fashioned in a looped configuration, whereas all upper-arm AVGs are tunneled straight.
Patients are seen 1 to 2 weeks after their initial BVAVF and AVG operations, and for BVAVFs, are also seen 4 to 6 weeks from anastomosis creation to evaluate for superficialization or transposition. In the setting of any complications, patients are seen earlier, either urgently in clinic or in the emergency department. BVAVF patients are also seen for follow-up 1 to 2 weeks after their secondstage surgery. Patients were subsequently monitored by nephrology and at their respective HD centers and were only seen by vascular surgery again if any complications arose.
Definitions. Functional patency was defined as the ability to cannulate the access site, maintain a minimum flow of 400 mL/min, and complete a session of HD in <4 hours. Primary assisted patency was defined as the period beginning with fistula creation to the time of first thrombosis, or "thrombosis-free access survival." This interval included any interventions required to maintain access patency. Primary functional assisted patency was defined as the period beginning with first functional cannulation to the time of first thrombosis, also including any interventions required to maintain flow. Functional secondary patency was defined as the period beginning with first functional cannulation to the time of abandonment. Primary failure included those accesses that did not mature, those that thrombosed early, and those that experienced significant complications requiring abandonment of the access before use. These definitions are consistent with those set forth in the vascular surgery literature by Sidawy et al 19 and Huijbregts et al. 20 Outcomes of interest. Our primary outcome was 1-year primary functional assisted patency. Secondary outcomes included 1-year primary assisted patency, 1-year secondary functional assisted patency, and complications. The complications included were vascular steal syndrome, hematoma, upper extremity edema, and wound infection. All patients lost to follow-up were excluded.
Statistical methods. Data were analyzed using SAS 9.3 (SAS Institute Inc, Cary, NC) and Epi Info 7, build 7.1.5.2 (Centers for Disease Control and Prevention, Atlanta, Ga) software. Continuous variables were analyzed using the Student t-test, but in the presence of significant variance, the Kruskal-Wallis test was used instead. Categoric variables were analyzed using the c 2 test if all cells had expected values >5 and a Fisher exact test if any expected values were <5. Statistical significance was set at a P value of <.05. A Kaplan-Meier analysis was performed comparing our primary and secondary outcomes between the two groups.
Because there was a statistically significant difference in the anesthesia type used between the two baseline cohorts and a trend toward a greater proportion in the baseline AVG cohort that had undergone prior access surgery than in the BVAVF cohort (50% vs 28%), we also performed a subgroup analysis for patients in whom the BVAVF or the AVG was their first HD access surgery, and there were no differences in type of anesthesia.
RESULTS
The study period included 61 patients (57% male): 29 (48%) who underwent BVAVF and 32 (52%) who underwent AVG. More than 90% of HD accesses created at our institution are autogenous, which explains the small number of AVGs performed during this period. Most were performed in the left upper extremity (87%). Overall, 67% had diabetes mellitus, and 89% had hypertension. There were 62% with a CVC present, 62% were actively on HD, and 39% had undergone prior HD access surgery. The mean follow-up was 21 6 17 months (range, 1.5-62 months). The median number of days between stages of BVAVF creation was 58 (interquartile range, 48-145).
Comparison of groups. Patient demographics are summarized in Table I . The BVAVF and AVG groups were not significantly different with respect to age, male sex, diabetes mellitus, or hypertension. As mentioned, more patients in the AVG cohort tended to have had prior access surgery (50% vs 28%). In addition, patients in the BVAVF group were less likely to have a CVC present (34% vs 88%; P < .001) and less likely to already be undergoing HD (34% vs 88%; P < .001). The first stage of a BVAVF was more likely to be performed under local anesthesia (79% vs 53%; P ¼ .03). The difference in the number of operations performed under regional anesthesia was not significant. General anesthesia was more likely to be used for AVGs (19% vs 0%; P ¼ .02).
Outcomes. Outcomes are summarized in Table II . The primary outcome of 1-year primary functional assisted patency was not significantly different between the two groups (45% vs 25%; P ¼ .04). However, BVAVFs demonstrated higher 1-year primary patency (62% vs 25%; P < .01), 1-year primary assisted patency (66% vs 41%; P ¼ .05), and a lower rate of interventions required to maintain or improve functionality after initiation of access use (10% vs 44%; P < .01). The 1-year secondary functional patency was similar between BVAVFs and AVGs (52% vs 47%; P ¼ .7). There were no significant differences with respect to primary failure (28% vs 34%; P ¼ .6), vascular steal syndrome (3% vs 6%; P ¼ 1), or overall complications (3% vs 9%; P ¼ .6). The median time to cannulation was significantly longer in the BVAVF group (141 vs 29 days, P < .001). Table III demonstrates the breakdown of causes of primary failure. Neither group experienced any significant upper extremity swelling. Kaplan-Meier curves (Figs 1 and 2) show the primary functional assisted patency was not significantly different (P ¼ .2). However, the primary assisted patency was significantly greater (P ¼ .03) for BVAVFs.
Subgroup analysis: comparison of groups. Baseline demographics are summarized in Table IV . Although patients in the BVAVF group were slightly younger (62 vs 56 years, P ¼ .03), there were no significant differences with respect to male sex, diabetes mellitus, or hypertension. Patients in the BVAVF group were still less likely to have a CVC present (19% vs 75%; P < .001) and still more likely to actively be on HD (75% vs 4%; P < .001). There were no differences with respect to the type of anesthesia used in this subgroup.
Subgroup analysis: outcomes. Subgroup outcomes are summarized in Table V . The primary outcome (1-year primary functional assisted patency) was significantly greater in the BVAVF cohort (52% vs 19%; P < .05). There were no significant differences with respect to the 1-year primary patency rates, 1-year primary assisted patency rates, or the 1-year secondary functional patency rates. BVAVFs still required a lower rate of interventions to maintain or improve functionality after initiation of access use (5% vs 44%; P ¼ .01).
DISCUSSION
The goal of the present study was to determine if the BVAVF was a viable alternative to the AVG in patients with inadequate superficial venous anatomy. The primary finding was that BVAVFs had outcomes that were not significantly different from AVGs, including similar 1-year primary functional assisted and 1-year secondary functional patency. BVAVFs did, however, demonstrate greater 1-year primary patency and were also less likely to require any reinterventions to preserve or maintain patency after their initial use than AVGs. The patency rates for BVAVFs in the present study compare favorably with the literature (Table VI) . In addition, BVAVFs demonstrated superior 1-year primary functional assisted patency than AVGs in access-naïve patients. A disadvantage of BVAVFs is a much longer time needed to achieve functional patency. Thus, in patients with poor superficial venous anatomy, one must decide whether the potential benefits of improved primary patency, avoidance of prosthetic graft, and decreased need for interventions outweigh the risks of delayed maturation, particularly if the patient is already undergoing HD via a CVC. Our study suggests that, at least in access-naïve patients, BVAVFs are superior to AVGs and should strongly be considered in the right subset of patients. compared with AVGs, cuffed CVCs, and uncuffed CVCs, respectively. 4 The relative mortality risk for patients with an AVG is also 1.4-times greater than for those with autogenous access. 7 In addition, AVF creation does not preclude one from creating an AVG should that AVF fail to mature. BVAVFs should be considered in patients with poor superficial venous vasculature if they are referred early enough to allow for maturity before their onset of HD. AVFs often require more procedures to achieve maturity and thus have longer prolonged tunnel catheter dwell times than AVGs. 21 Catheter dwell times of at least 6 months have been shown to correlate with a 50% incidence of catheter-related bacteremia and a 1-year relative mortality risk of 3.4. 22, 23 Furthermore, Greenberg et al 24 showed a benefit for BVAVFs with improved patency only if patients were referred 3 months before their onset of HD.
Other subsets of patients that may benefit from a BVAVF are those with systemic infection and those who are HIV positive. 25 Its usage has been described in a patient with methicillin-resistant Staphylococcus aureus bacteremia and poor superficial upper extremity venous vasculature. Given his need for prolonged intravenous antibiotics and the contraindication to foreign body material in the setting of bacteremia, the authors decided to place a BVAVF, with good results. 26 The data have also shown that HIV-positive patients have higher rates of complications and failure of AVG than with autogenous access, and thus one might consider a BVAVF in this population as well should they have inadequate superficial veins. [27] [28] [29] Successful creation of a BVAVF is more technically challenging than other AVFs. The brachial vein is more thin-walled than the cephalic or basilic vein and is thus more prone to injury, kinking, and twisting. It has innumerable tributaries, many of which are diminutive, that need ligation. 30 The vein is sometimes adherent to the brachial artery and may course under the artery and median nerve. Anecdotally, the vein tends to dilate less when distended with heparinized saline and seems to require more time to mature than the basilic vein. Thus, although we use a minimum threshold of 2.5 mm to create the BVAVF, we prefer a brachial vein of at least 3 mm. Unlike the brachiobasilic AVF, where controversy exists about whether it should be performed in one or two stages, we believe the BVAVF should always be done in two stages. The two-stage approach is supported by the literature. 11, 12 Finally, because of its depth (particularly in large arms), to superficialize the BVAVF, we almost routinely transect the fistula (which is created at the elbow), transpose it, and perform a new anastomosis to the brachial artery above the elbow. Some degree of forearm swelling often occurs in patients with a BVAVF. Typically, this swelling is self-limiting and does not result in any significant sequelae. However, when a BVAVF occludes, there is a theoretical concern that pronounced swelling or phlegmasia may occur. Fortunately, we did not observe such severe swelling in our patient population. Perhaps this was because most of these fistulas were created in patients with an intact, albeit small, superficial venous system.
Our study has several limitations. Its retrospective nature inherently introduces the possibility for confounding and bias. Our overall sample size is small, albeit comparable with other series. Because of the sample size limitation and the small numbers with the outcome of interest, even after removing those who had undergone prior access surgery, a larger proportion of those in the AVG cohort were currently on HD (eg, through a CVC). In addition, follow-up for dialysis patients to determine patency is always a challenge and made more difficult because our program is a safety-net hospital. Finally, the AVG patency in our study was significantly lower than in other published series. This may reflect the fact that a prior access had already failed in more than half and that we focused exclusively on patients with poor superficial venous anatomy.
CONCLUSIONS
The BVAVF is a viable alternative to the AVG in patients with inadequate superficial venous anatomy, especially in access-naïve patients. The decision to perform BVAVF must be weighed against the delay in functional maturation expected compared with AVG. In access-naïve patients with inadequate superficial veins who will have sufficient time for an AVF to mature, one should strongly consider performing a BVAVF instead of an AVG. 
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